Technology
Engage with the leading edge of biopharmaceuticals

Tumor Killing

BXQ-350 nanovesicles have potent killing activity in vitro on more than 60 human cancer cell lines. In vivo experiments in laboratory animals have shown significant inhibition and elimination of tumors in all tested models including gliomas, human squamous cell carcinoma, neuroblastoma, malignant peripheral nerve sheath tumor, head & neck cancer, acute lymphoblastic leukemia (ALL) and pancreatic cancer. Recent data show that our nanovesicles provide synergistic efficacy with current standard of care chemotherapies.

Mechanism-of-action studies indicate that BXQ-350 accelerates inherent cellular digestive processes to kill tumor cells.

BXQ-350 has been shown to reduce tumor volume in both in vitro and in preclinical, orthotopic mouse models of glioblastoma. High dose preclinical acute mouse studies also indicate low toxicity.

Glioma Orthotopic Model

Aggressive brain tumor cells were implanted into 4 living mice.

Mice 1 and 2 were treated with BXQ-350 on days 5, 7, 9, 12, 14, 16;
Mice 3 and 4 received no treatment.